Aura Biosciences, Inc.
Aura Biosciences, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Biological Products, (No Diagnostic Substances).
The next scheduled catalyst is Next quarterly earnings (projected) on November 11, 2026, a projected date rather than a confirmed one. There are 4 upcoming events on record.
Cash runway is approximately 6.8 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
| Date | Event | Type | Phase |
|---|---|---|---|
| November 11, 2026 est. | Next quarterly earnings (projected) | Earnings | — |
| November 30, 2026 | Suprachoroidal Administration in Subjects With Metastases to the Choroid | Trial Milestone | Phase 2 |
| March 15, 2027 | A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer | Trial Milestone | Phase 1 |
| November 15, 2027 | A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma | Trial Milestone | Phase 3 |
Track AURA alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open AURA in the tracker| Date | Event | Type | Phase |
|---|---|---|---|
| August 11, 2026 | Quarterly results filed (8-K) | Earnings | — |
| July 8, 2026 | 8-K filed: Leadership change | Corporate | — |
| May 11, 2026 | Quarterly results filed (8-K) | Earnings | — |
| May 5, 2026 | 8-K filed: Material agreement | Corporate | — |
| May 4, 2026 | 8-K filed: Leadership change, Reg FD disclosure, Other event | Corporate | — |
| May 4, 2026 | Quarterly results filed (8-K) | Earnings | — |
| March 30, 2026 | Quarterly results filed (8-K) | Earnings | — |
| November 13, 2025 | Quarterly results filed (8-K) | Earnings | — |
| August 13, 2025 | Quarterly results filed (8-K) | Earnings | — |
| May 16, 2025 | 8-K filed: Material agreement, Other event | Corporate | — |
| May 15, 2025 | Quarterly results filed (8-K) | Earnings | — |
| April 22, 2024 | Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma | Trial Milestone | Phase 2 |
| January 26, 2021 | Study in Subjects With Small Primary Choroidal Melanoma | Trial Milestone | Phase 1/Phase 2 |
Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.